A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia
- 1 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biomedical Engineering
- Vol. 4 (1), 40-51
- https://doi.org/10.1038/s41551-019-0503-3
Abstract
Acute myeloid leukaemia (AML) is a malignancy of haematopoietic origin that has limited therapeutic options. The standard-of-care cytoreductive chemotherapy depletes AML cells to induce remission, but is infrequently curative. An immunosuppressive AML microenvironment in the bone marrow and the paucity of suitable immunotherapy targets limit the induction of effective immune responses. Here, in mouse models of AML, we show that a macroporous-biomaterial vaccine that delivers the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the Toll-like-receptor-9 agonist cytosine-guanosine oligodeoxynucleotide and one or multiple leukaemia antigens (in the form of a defined peptide antigen, cell lysates or antigens sourced from AML cells recruited in vivo) induces local immune-cell infiltration and activated dendritic cells, evoking a potent anti-AML response. The biomaterial-based vaccine prevented the engraftment of AML cells when administered as a prophylactic and when combined with chemotherapy, and eradicated established AML even in the absence of a defined vaccine antigen. Biomaterial-based AML vaccination can induce potent immune responses, deplete AML cells and prevent disease relapse. A macroporous material encapsulating an immune-cell-activating cytokine, an adjuvant and tumour-associated antigens elicits prophylactic immunity to acute myeloid leukaemia in mice, and eradicates the disease when combined with chemotherapy.Funding Information
- Cancer Research Institute
- National Science Foundation
- U.S. Department of Health & Human Services | National Institutes of Health (U19HL129903, R01CA223255, R01EB023287, U01CA214369)
This publication has 50 references indexed in Scilit:
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature Medicine, 2013
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Immunotherapy prospects for acute myeloid leukaemiaClinical and Experimental Immunology, 2010
- A self-assembling peptide acting as an immune adjuvantProceedings of the National Academy of Sciences of the United States of America, 2009
- In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in MiceScience Translational Medicine, 2009
- Mouse models of human AML accurately predict chemotherapy responseGenes & Development, 2009
- Infection-mimicking materials to program dendritic cells in situNature Materials, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006